Find Academic Supervisors

M Reza KholghyView profile

Associate Professor

• Industrial Decarbonization
• Hydrogen Production
• Carbon Dioxide Conversion
• +7 more

Dr. M Reza Kholghy is an Associate Professor and Canada Research Chair in Particle Technology and Combustion Engineering at Carleton University's Department of Mechanical and Aerospace Engineering. He directs the Energy and Particle Technology Laboratory (EPTL) where he focuses on sustainable industrial solutions. His academic credentials include a BASc in Aerospace Engineering from Sharif University of Technology, and MASc/PhD degrees in Mechanical Engineering from the University of Toronto, followed by postdoctoral work at ETH Zurich. Research interests center on: Industrial decarbonization through metal fuel combustion (aluminum/iron) and carbon management Hydrogen production via methane pyrolysis and metal-water reactions Advanced material synthesis including flame spray pyrolysis for catalytic films and alumina production Nanoparticle engineering with focus on soot formation dynamics and optical properties His publications predominantly explore nanoparticle synthesis mechanisms, soot formation modeling, and sustainable fuel technologies, with recent emphasis on hydrogen cogeneration and metal combustion. Experimental and computational approaches are equally represented across combustion diagnostics, reactor design, and molecular dynamics simulations. Major scientific recognitions include: Canada Research Chair (Tier 2) Vanier Canada Graduate Scholarship NSERC Postdoctoral Fellowship He leads the Energy and Particle Technology Laboratory with industry partnerships focused on sustainable technology development. The lab specializes in flame spray pyrolysis reactors, nanoparticle characterization (surface area, porosity, composition), and high-pressure reaction systems. Dr. Kholghy actively mentors students through capstone projects and research positions, though specific PhD/Master's advisees aren't named in available sources.

• Exercise Physiology
• Diabetes
• Cardiovascular Disease
• +4 more

Brett Gordon is an Associate Professor in Exercise Physiology and Head of Department for Rural Clinical Sciences at La Trobe University's Rural Health School in Bendigo, Australia. He is also an Accredited Exercise Physiologist (AEP) with over a decade of academic experience and nearly ten years of clinical practice. PhD from Royal Melbourne Institute of Technology University (2012) MAppSc (Exercise Rehabilitation) from Victoria University BAppSci (Human Movement) from Royal Melbourne Institute of Technology University Professor Gordon's research focuses on the role of exercise in managing chronic disease, particularly examining how exercise can be optimally assessed and prescribed for people with cardiometabolic health conditions. His work utilizes continuous glucose monitoring systems, accelerometers, and GPS monitors to study both healthy individuals and those with health conditions. Early in his career, he investigated exercise benefits for children with chronic fatigue syndrome before shifting focus to cardiometabolic health. Analysis of his recent publications reveals a strong emphasis on practical applications of exercise physiology in real-world settings, particularly in rural communities. His research spans walking football programs for older adults, optimal exercise dosing for cardiac rehabilitation, e-bike health benefits, military transition health issues, and telehealth applications for cardiac rehabilitation. A consistent theme across his work is addressing health disparities in rural populations. Member of Exercise and Sports Science Australia (ESSA), Research Committee Associate Editor for Frontiers in Sports and Active Living Member of Scientific Reports Editorial Board Member of American Association of Cardiovascular and Pulmonary Rehabilitation Professor Gordon has successfully supervised numerous students to completion, including 3 honours students (all H1), 1 master's student, and 5 doctoral students. He currently supervises 5 PhD candidates and 2 Master by Research candidates. His funded research includes projects on walking football for older adults and exercise demands in adolescent athletes. He maintains a broad collaborative network including institutions such as Auckland, Swinburne, Sheffield Hallam, Murdoch, RMIT, and Deakin universities, as well as Bendigo Health, The Austin Hospital, and the Baker IDI Heart and Diabetes Institute. His current research projects focus on prediabetes, diabetes, heart disease, hospital care, military transition, and resistance training, demonstrating his commitment to translating exercise science into practical health interventions for diverse populations.

• Biomedical Engineering
• Mechanical Engineering
• Rheology
• +7 more

Mingyang Tan is a Postdoctoral Research Associate at the Department of Mechanical and Industrial Engineering, Northeastern University. Their research focuses on intersections of biomedical engineering, rheology, 3D printing, and materials science, with applications in pharmaceutical manufacturing and biofluid dynamics. Role: Postdoctoral Research Associate Department: Mechanical and Industrial Engineering Email: mi.tan@northeastern.edu Research Interests Mingyang Tan's work explores rheological properties of complex systems, including 3D bioprinting for tissue engineering, magnetic particle dynamics in fluids, and microrheology of biofluids. Their studies address biomedical applications like plasma coagulation and osteochondral graft development, alongside innovations in pharmaceutical manufacturing using binder jetting 3D printing . Publication Trends Recent articles highlight advances in additive manufacturing , biomaterials , and microrheology , particularly for medical and pharmaceutical contexts. Key themes include magnetic alignment of particles, sustained drug delivery , and anisotropic suspensions . The work spans computational simulations, experimental validations, and translational applications. Scientific Awards Advising & Grants No formal advising or grant information is explicitly mentioned in the provided text. Labs & Collaborations Details about specific labs, teams, or collaborative networks are unavailable in the provided materials.

Lennart BeckmannView profile

Assistant Clinical Professor

• Hematology
• Oncology
• Thrombosis
• +3 more

Lennart Beckmann is an Clinical Assistant Professor at the University Medical Center Hamburg-Eppendorf, affiliated with the II. Medical Clinic and Polyclinic under the Faculty of Medicine. His research focuses on hematology and oncology, particularly investigating coagulation mechanisms in cancer and hematological disorders. He has contributed to studies on tumor-induced thrombosis, immune checkpoint inhibitors, and the role of myeloperoxidase in anticoagulant therapies. Beckmann has published extensively in journals like J Thromb Haemost and Hamostaseologie , addressing topics such as extracellular vesicle-mediated coagulation and small-molecule inhibitors for factor XI. He holds awards including the 2029 Young Investigator Award (DGHO) and the 2019 Dieter Kurt Hossfeld Prize for clinical oncology/hematology. His work bridges clinical research and translational medicine, with a focus on improving understanding of thrombotic complications in cancer and autoimmune conditions. Collaborations include studies on drug repurposing (e.g., bacitracin, rutin) and mechanisms of acquired protein S deficiency. Beckmann’s research also examines the interplay between inflammation, monocyte activation, and coagulation pathways in diseases like antiphospholipid syndrome and acute myeloid leukemia.

Jonathan DouxfilsView profile

Professor

• Hematology
• Pharmacology
• Thrombosis Research
• +3 more

Jonathan Douxfils is a Professor at the University of Namur, affiliated with the Namur Research Institute for Life Sciences and the Thrombosis and Hemostasis Center. His expertise lies in pharmacology, thrombosis, and anticoagulant therapies. He holds a Pharm.D. and Ph.D. from the University of Namur and a Master of Pharmacy from Université Catholique de Louvain. Key roles include CEO of Qualiblood, Co-Chairman of the International Society on Thrombosis and Hemostasis's SSC Control of Anticoagulation, and Pharmacovigilance Expert at the Federal Agency of Medicines and Health Products. His research focuses on anticoagulant safety, thrombosis risk assessment, and innovative diagnostic tools like the DOAC Dipstick. Notable awards include the Alfers Prize 2022, Eberhard F. Mammen Young Investigator Award 2019, and multiple recognition in hemostasis research. He leads projects such as NucleoGlio (glioblastoma diagnostics) and GT4HEALTH (gene therapy research). He has supervised 19 thesis works and contributed to over 436 research outputs. His work aligns with UN SDGs in health and innovation.

Daniel Ortega PonceView profile

Senior Lecturer

• Nanomedicine
• Magnetic Hyperthermia
• Biomedical Engineering
• +3 more

Prof. Daniel Ortega Ponce is a Senior Lecturer at the University of Cádiz's Condensed Matter Physics Department. He holds a PhD in Condensed Matter Physics from the University of Cádiz (2007) and has held positions including Ramón y Cajal Researcher (2020-2024), Marie Curie Fellow at University College London (2009-2012), and leadership roles in institutions like IMDEA Nanoscience and INiBICA. His research focuses on magnetic nanoparticles for biomedical applications, including hyperthermia, tissue engineering, and nanomedicine. Education: BSc in Chemistry of Materials (University of Cádiz, 2001) MSc in Industrial Process Engineering (2003) PhD in Condensed Matter Physics (2007) Research interests span nanomaterials for hyperthermia, magnetic nanoparticle synthesis, and in vivo thermal diagnostics. He leads the Nanoteranostics group at INiBICA and coordinates national and European networks in nanomedicine. Awards include EPSRC Peer Review College membership and Marie Curie fellowships. His work bridges physics, materials science, and clinical translation, with over 60 publications and 15 invited conference talks. Scientific awards include: Ramón y Cajal Researcher (2020-2024) EPSRC Peer Review College Member COST Action Coordinator (RADIOMAG, 2014-2018) Grants and collaborations involve leadership in the RedLab In Silico Electromagnetic Testing Lab and advisory roles for EU and international funding bodies. His research emphasizes computational modeling (in silico) for hyperthermia safety and efficacy, alongside experimental advancements in nanoparticle design.

Jeffrey WeitzView profile

Professor

• Thrombosis
• Hemostasis
• Atherosclerosis
• +3 more

Dr. Jeffrey Weitz is a Professor in the Departments of Medicine and Biochemistry and Biomedical Sciences at McMaster University, and serves as Executive Director of the Thrombosis and Atherosclerosis Research Institute (TaARI). He holds prestigious academic titles including the Tier I Canada Research Chair in Thrombosis and the Fraser Mustard Chair in Cardiovascular Research. His research focuses on hemostasis, thrombosis, and anticoagulant therapies, with a particular emphasis on developing safer anticoagulants targeting factor XI and improving medical device biocompatibility. Dr. Weitz leads a multidisciplinary team investigating mechanisms of thrombosis, clot formation regulation, and novel therapies to reduce cardiovascular-related mortality. His work spans translational research, clinical trials, and epidemiological studies, with contributions to understanding polyphosphate's role in coagulation and the development of clot-resistant medical device coatings. TaARI, under his leadership, bridges basic and clinical research to address thrombosis and bleeding disorders. Key achievements include advancements in factor XI inhibition and the design of anti-thrombogenic materials. Research Clusters: Health & Bio-innovation Key Awards: Tier I Canada Research Chair, Fraser Mustard Chair Labs: Weitz Lab (focusing on coagulation mechanisms and anticoagulant development) Dr. Weitz collaborates with bioengineers to innovate biomaterials and devices, while maintaining clinical relevance through anticoagulant trials like AXIOMATIC-TKR and AZALEA-TIMI 71. His lab's recent studies explore histidine-rich glycoprotein's role in clotting regulation and polyphosphate toxicity mitigation.

Mary Beth GrahamView profile

Professor

• Infectious Disease
• HIV Infection
• Infections in Immunocompromised Patients
• +4 more

Mary Beth Graham, MD, FIDSA, FACP is a Professor of Medicine with tenure at the Medical College of Wisconsin, where she serves as Associate Chief for the Division of Infectious Disease. She is also the Medical Director of Infection Prevention and Control at Froedtert Hospital and the Infection Prevention Program Director for the Medical College of Wisconsin. Dr. Graham is a Board Certified Internist and Infectious Disease specialist who joined the faculty at the Medical College of Wisconsin as an Assistant Professor of Medicine/Infectious Diseases in February 2002. Dr. Graham received her MD from Northwestern University Medical School in Chicago (1984), completed her Residency in Internal Medicine at the University of Washington Affiliated Hospitals in Seattle (1984-1987), and completed her Fellowship in Infectious Diseases at Washington University School of Medicine in St. Louis (1988-1991). Dr. Graham's clinical expertise includes HIV infection and associated complications, infections in immunocompromised individuals (including transplant recipients), influenza treatment and prevention, and the prevention of transmission of hospital-associated infections. She has an active outpatient clinical practice and also attends on the inpatient transplant and general infectious disease services. Her research has focused on infection control, particularly related to C. difficile, carbapenem-resistant organisms, and most recently on COVID-19 related complications including thrombosis and immune responses. Her publication record demonstrates a strong focus on clinical infectious disease research, with numerous studies on infections in immunocompromised hosts, antimicrobial resistance, and viral pathogenesis. Her work spans clinical trials, epidemiological studies, case reports, and immunological investigations, showing both clinical relevance and scientific rigor across multiple sub-specialties within infectious diseases. Best Doctors in America Top Doctor (Castle Connolly/Milwaukee Magazine) Best Teaching Physician at Froedtert Hospital by Department of Medicine residents (2013) MCW Outstanding Medical Student Teacher award (2015) Dr. Graham has demonstrated exceptional commitment to medical education, having received multiple teaching awards. As the Infectious Disease Fellowship Program Director, she plays a pivotal role in training the next generation of infectious disease specialists. Her administrative leadership in infection prevention and control reflects her significant contributions to hospital epidemiology and patient safety, with practical applications of her research directly impacting clinical practice and hospital policy. Dr. Graham maintains an active clinical practice with a focus on complex infectious disease cases, particularly in immunocompromised patients. Her dual expertise in clinical care and infection prevention makes her a key resource for managing challenging cases and developing institutional protocols for infection control.

Christopher R MuellerView profile

Professor

• Epigenetics and epigenomics
• Transcriptomics
• Genomics
• +5 more

Christopher R. Mueller is a Full Professor in the Department of Biomedical and Molecular Sciences at the School of Medicine, Faculty of Health Sciences, Queen's University at Kingston. He has been a full professor since June 2006 and maintains his research laboratory at the Cancer Research Laboratories located at 10 Stuart St, Kingston, ON. Dr. Mueller is also affiliated with the Cancer Biology & Genetics division of the Queen's Cancer Research Institute and is a member of the Translational Institute of Medicine (TIME). Dr. Mueller received his BSc Honours in Integrated Science Studies from Carleton University (1980), followed by a PhD in Microbiology and Immunology from McGill University (1986), and completed his Post-Doctoral Fellowship in Molecular Biology at the University of Geneva (1989). His primary research focuses on developing liquid biopsy approaches for cancer detection and monitoring. His laboratory has pioneered DNA methylation-based blood tests for various cancers including breast, lung, prostate, ovarian, and pancreatic cancers. A key aspect of his work involves studying the relationship between the Glucocorticoid Receptor, BRCA1, and the Estrogen Receptor in breast tumorigenesis. His research identified methylation of the Glucocorticoid Receptor promoter as a potential biomarker predicting lack of response to anti-estrogen therapy in estrogen receptor-positive breast cancer patients. Dr. Mueller's recent publications demonstrate a strong focus on translating laboratory discoveries into clinical applications. His work on DNA methylation-based liquid biopsies spans multiple cancer types, with particular emphasis on breast cancer subtypes. The research shows a progression from basic molecular mechanisms to clinical validation studies, highlighting his commitment to translational research that directly impacts patient care. A DNA methylation-based liquid biopsy for triple-negative breast cancer (2021) Development and initial clinical correlation of a DNA methylation-based blood test for prostate cancer (2020) Region-specific glucocorticoid receptor promoter methylation studies in breast cancer (2019) Through his research, Dr. Mueller is helping transform oncology practice by developing tools that enable earlier cancer detection, better treatment selection, and more effective monitoring of treatment response. His work bridges basic molecular research with clinical applications, positioning him at the forefront of precision oncology.

Marlene BarrosView profile

Professor

• Protein Chemistry
• Molecular Mechanisms of Disease
• Biomarker Discovery
• +7 more

Marlene Barros is a Full Professor at the Faculty of Dental Medicine (FMD), Portuguese Catholic University (UCP), where she also serves as Director since 2020. She is the Director of the Center for Interdisciplinary Research in Health (CIIS), recognized as 'Very Good' by FCT, and leads the SalivaTec laboratory focused on saliva-based diagnostics. She has a strong academic background in biochemistry and biology, with leadership roles in education and research. Her educational qualifications include: PhD in Biochemistry (specialty: Enzymology and Protein Chemistry), University of Coimbra (1995) Agregação in Biology, University of Aveiro (2007) Marlene Barros' research is centered on protein chemistry and molecular mechanisms of disease, with a focus on identifying biomarkers for diagnosis and therapeutic targeting. Her work spans proteomics, bioinformatics, oral biology, and microbiome analysis. She has coordinated academic programs such as the Master in Molecular Microbiology and the Degree in Biomedical Sciences. Her recent research articles reflect a strong trend in salivary proteomics, oral microbiome interactions, human-viral interactomics, and the development of bioinformatics databases (e.g., OralOme, OvisOme, CanisOme). These works emphasize translational applications in precision medicine, diagnostics, and functional food science. She has received the following scientific award: Prémio Melhor Poster SciComPT 2019 She has supervised numerous academic projects and is actively involved in national and international research collaborations. She has led or participated in significant funded projects such as SPRINT, OralTherm, RedSup4Health, and OeHMP, supported by Portugal2020 and Fundación 'la Caixa'. Her work contributes to UN Sustainable Development Goals, particularly in health and education. She is a key member of the SalivaTec laboratory and contributes to interdisciplinary teams in projects involving digital health, oral microbiome, and functional foods. Her leadership extends to pedagogical innovation and community-based learning in dental education.

Juan R. CebralView profile

Professor

• Computational Fluid Dynamics
• Hemodynamics
• Cerebral Aneurysms
• +7 more

Juan R. Cebral is a Professor in the Departments of Bioengineering and Mechanical Engineering at the Volgenau School of Engineering, George Mason University. He leads the Computational Hemodynamics Laboratory and maintains affiliations with the Center for Computational Fluid Dynamics and the Krasnow Institute for Advanced Studies. His research bridges engineering and medicine to address life-threatening vascular conditions through computational modeling. He earned his PhD in Computational Sciences and Informatics from George Mason University in 1996 and completed his MSc in Physics at the University of Buenos Aires, Argentina in 1991. Originally from Plaza Huincul in Patagonia, Argentina, he has built an internationally recognized research program focused on patient-specific modeling of cerebral blood flow. Professor Cebral's research centers on using computational fluid dynamics to model hemodynamics in cerebral aneurysms and other vascular diseases. His work investigates the relationship between blood flow patterns and aneurysm development, rupture, and treatment outcomes, with particular focus on flow diversion techniques. His lab develops methods for constructing patient-specific anatomical models from medical images and applies them to enhance risk assessment and personalize endovascular treatments. His research has been funded by the National Institutes of Health, American Heart Association, Whitaker Foundation, and industry partners including Philips Healthcare and Boston Scientific. His recent publications (2024-2025) demonstrate continued focus on cerebral aneurysm hemodynamics with increasing attention to flow diversion mechanisms, fibrin accumulation, and aneurysm wall integrity. His work integrates computational modeling with biological and clinical data to better understand aneurysm growth patterns, rupture risks, and treatment outcomes, featuring sophisticated multi-scale modeling approaches that connect hemodynamic conditions with biological responses in the vessel wall. His research has been funded by prestigious organizations including the National Institutes of Health, American Heart Association, and Whitaker Foundation His work has been featured in Forbes Argentina (August 5, 2024 and October 7, 2024) His student Medhini Sosale earned the prestigious Goldwater Scholarship (April 12, 2022) Professor Cebral mentors students in bioengineering research, with several advisees receiving significant recognition. His research program is supported by multiple NIH grants including R01 NS076491 (Computational and Biological Approach to Flow Diversion) and R21 NS094780 (Improved evaluation of PCOM aneurysms), as well as funding from Philips Medical Systems and Mayo Clinic. He collaborates extensively with clinicians at Inova Fairfax Hospital, Mayo Clinic, and international institutions to translate computational findings into clinical practice. He directs the Computational Hemodynamics Laboratory at George Mason University, which specializes in patient-specific modeling of blood flows in cerebral aneurysms. The lab works closely with the Center for Computational Fluid Dynamics and collaborates with clinicians and researchers from Inova Fairfax Hospital, Mayo Clinic, Allegheny General Hospital, Kuopio Medical Center in Finland, Clinica ENERI in Argentina, University of Pittsburgh, and Barcelona Supercomputing Center.

• Medical Biochemistry
• Clinical Biochemistry
• Oxidative Stress
• +5 more

Prof. Dr. Aynur KIRBAŞ is a distinguished Professor of Medical Biochemistry at Ahi Evran University, Faculty of Medicine, where she has served since 2023. Previously, she was an Associate Professor at Kırşehir Ahi Evran University (2022-2023) and Recep Tayyip Erdoğan University (2013-2022), and an Assistant Professor at Recep Tayyip Erdoğan University (2009-2013). She currently serves as both Professor and Head of Department at Ahi Evran University, and as Education Coordinator since 2025. Dr. KIRBAŞ earned her Bachelor's Degree from Atatürk University, Faculty of Medicine (1994-2000) and completed her PhD/Medical Specialization at Süleyman Demirel University, Faculty of Medicine Hospital Application and Research Center (2002-2007). She has obtained proficiency in English with a score of 77 on the ÜDS exam in Fall 2010. Her research focuses on medical biochemistry, particularly oxidative stress, inflammation markers, and biomarker research in various clinical conditions. With 102 publications to her name including 84 articles, she has made significant contributions to understanding biochemical markers in neurological disorders, cardiovascular disease, metabolic conditions, and inflammatory processes. Her work frequently examines YKL-40, copeptin, and other novel biomarkers across diverse clinical settings from stroke to rheumatological conditions. Dr. KIRBAŞ has led or participated in 17 research projects, primarily funded by higher education institutions, investigating topics ranging from hirudotherapy effects to novel inflammatory markers in pleural effusion. Her most recent projects examine the effects of hirudotherapy on exercise-induced fatigue and the relationship between serum BDNF and NGF levels in restless leg syndrome. She has received recognition for her work, including an award in 2006 for research on lisinopril's effects on lipid peroxidation in hypertensive rats. Her scholarly impact is evident with 675 citations and an h-index of 16 according to UNIS metrics. Dr. KIRBAŞ actively contributes to her field through editorial work for journals including Current Research in Health Sciences and The Eurasian Journal of Medicine, and maintains professional memberships in the Turkish Clinical Biochemistry Association, Turkish Biochemistry Association, and Clinical Biochemistry Specialists Association. Her teaching portfolio includes numerous biochemistry courses covering topics from vitamin metabolism to laboratory quality control.

• Microfluidics
• Point-of-care diagnostics
• Antibiotic susceptibility testing
• +4 more

Dr. Al Edwards is a Professor in the Department of Pharmacy within the School of Chemistry, Food and Pharmacy at the University of Reading. His extensive research portfolio spans over two decades, with a clear evolution from immunology and dendritic cell biology in his earlier career to his current focus on microfluidic diagnostic devices and point-of-care testing technologies. Professor Edwards' research interests center on developing innovative diagnostic solutions, particularly in microfluidics and point-of-care testing. His work bridges engineering and clinical applications, with significant contributions to antibiotic susceptibility testing, vaccine delivery systems, and smartphone-based diagnostic platforms. His research has evolved from fundamental immunological studies to highly applied diagnostic device development, demonstrating a strong translational research trajectory. His publication record shows a clear trend toward practical diagnostic solutions with clinical applications, particularly in antibiotic susceptibility testing and point-of-care diagnostics. The integration of microfluidics, 3D printing, and smartphone technology represents the cutting edge of his current research, with numerous publications demonstrating how these technologies can be combined to create accessible diagnostic tools for resource-limited settings. Professor Edwards has been actively involved in mentoring researchers and collaborating across disciplines, as evidenced by his numerous co-authored publications. His work on diagnostic device usability and information design for self-testing demonstrates attention to the practical implementation challenges of diagnostic technologies. His laboratory appears to specialize in developing open-source, low-cost diagnostic platforms using Raspberry Pi systems, 3D printing, and microcapillary technologies. The Cygnus platform for smartphone-based diagnostics and the PiRamid imaging system represent significant contributions to making sophisticated diagnostic technologies more accessible.

Wolfgang BergmeierView profile

Professor

• Platelet Signaling
• Megakaryocyte Biology
• Small GTPase Signaling
• +4 more

Wolfgang Bergmeier, PhD, is a Professor in the Department of Biochemistry and Biophysics at the University of North Carolina at Chapel Hill. He is a member of the UNC Lineberger Comprehensive Cancer Center and the UNC Blood Research Center, where he leads research on the signaling mechanisms regulating megakaryocyte and platelet function in health and disease. His laboratory employs a multidisciplinary approach including biochemistry, cell and molecular biology, immunology, cutting-edge microscopy, and animal models to investigate platelet biology and its implications for human disease. Dr. Bergmeier's research focuses on understanding small GTPase signaling in platelets, particularly Rap1, and its role in hemostasis, thrombosis, and cancer. His work has made significant contributions to our understanding of how platelets secure vascular integrity, how they contribute to cancer progression and treatment complications, and how platelet function can be optimized for therapeutic purposes. His laboratory has developed novel mouse models and intravital imaging platforms to study platelet function in real-time. Analysis of Dr. Bergmeier's recent publications reveals a strong focus on platelet signaling mechanisms, particularly Rap1 and other small GTPases, and their implications for hemostasis, thrombosis, and cancer. His research spans from fundamental molecular mechanisms to translational applications, including development of novel antithrombotic strategies, optimization of platelet transfusion therapy, and understanding the complex relationship between platelets and cancer progression. Dr. Bergmeier has received numerous awards including the Outstanding Investigator Award from the National Heart, Lung and Blood Institute (NIH) in 2019, the American Heart Association ATVB Special Recognition Award in Thrombosis in 2016, and the Established Investigator Award from the American Heart Association in 2014. He has served as Chair of the 9th Symposium of Hemostasis in Chapel Hill (2018) and Vice Chair of the Gordon Research Conference on the Cell Biology of Platelets and Megakaryocytes (2017). He is also an Associate Editor for the Journal of Thrombosis and Hemostasis. His laboratory actively collaborates with clinical researchers at UNC, particularly with Dr. Nigel Mackman on cancer-related platelet research and with Drs. Flick and Wolberg on the interplay of platelets and the coagulation system. The Bergmeier Lab is part of the UNC BCBP Green Lab initiative, demonstrating a commitment to sustainability in research practices.

Jill JohnsenView profile

Professor

• Hematology
• Blood Disorders
• Genetics of Clotting Factors
• +4 more

Dr. Jill Johnsen is an Academic Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine. She serves as faculty at both the Institute for Stem Cell & Regenerative Medicine and the Center for Cardiovascular Biology at UW. Dr. Johnsen is also affiliated with the Washington Center for Bleeding Disorders, where she practices clinically. Education: M.D. from Case Western Reserve University Residency in Internal Medicine at University Hospitals of Cleveland Fellowship in Hematology/Oncology at University of Michigan Dr. Johnsen is a physician scientist specializing in classical hematology with a focus on von Willebrand disease, hemophilia, and blood group genetics. Her research program aims to improve diagnosis and care of patients with blood disorders through advancement of our understanding of the underlying biology. She leverages new technologies including targeted and whole genome next generation DNA sequencing, multi-omics, and long-read sequencing to study the genetics of clotting factors and blood groups, with particular emphasis on how bleeding uniquely impacts females. Analysis of Dr. Johnsen's recent publications reveals a strong focus on von Willebrand disease genetics, hemophilia research, and blood group antigen studies. Her work spans basic science investigations of coagulation factor biology to clinical studies examining diagnosis and treatment approaches. A consistent theme is the application of genomic technologies to understand bleeding disorders across diverse populations. Professional Activities: Active participant in the My Life, Our Future hemophilia genotyping initiative Contributor to NHLBI Exome Sequencing Project and TOPMed Program Regular presenter at hematology conferences including ISTH and ASH